Supplementation with n-3 PUFAs decreased HDL concentration inpatients with T2DM and CHD (WMD = –3.92, 95% CI =–6.35 to –1.48, p = 0.02 < 0.05), and no significantdifferences in LDL, triglycerides, cholesterol, and CRP in patients with T2DM andCHD (p> 0.05) (Table 2). The gene discussed is CRP; the disease is coronary artery disorder.